Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-07T20:17:54.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, while several key medical topics and terms related to lung cancer and pembrolizumab have been removed.
    Difference
    3%
    Check dated 2025-08-31T12:59:01.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-17T05:21:16.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-08-10T01:00:04.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    1%
    Check dated 2025-08-02T19:49:57.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-07-26T16:23:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.